Immunotherapy after radiation shows promise in rare lung cancer
NCT ID NCT02959463
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested whether giving the immunotherapy drug pembrolizumab (Keytruda) after radiation therapy is safe for people with malignant pleural mesothelioma, a rare cancer of the lung lining. Twenty-five participants received radiation followed by pembrolizumab. The study focused on side effects and also tracked survival. Results help guide future research but are not yet conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (Keytruda)
- What this could lead to
- If successful, this combination could offer a new treatment option for pleural mesothelioma, potentially improving survival.
- What could go wrong
- This is a very early phase 1 trial with only 25 participants, so results may not apply broadly. The main goal is safety, not yet effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MALIGNANT MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.